C22orf9 is a protein that is encoded by the C22orf9 gene, situated on the 22nd chromosome in humans. The specific functions and roles of C22orf9 remain largely undefined, and as such, it is designated as an open reading frame (orf), indicating that it is a segment of DNA that has been identified to potentially code for a protein but whose function is not yet clear.The research on proteins like C22orf9 typically involves a combination of bioinformatics approaches to predict protein structure and function, and experimental verification to confirm these predictions and to identify the protein's role in the cell. Such studies might explore the protein's expression patterns across different tissues and developmental stages, its subcellular localization, and its interactions with other proteins.The study of C22orf9 may reveal its participation in specific cellular pathways or processes, such as signal transduction, gene regulation, or metabolic pathways. It is also possible that C22orf9 could be implicated in disease processes if mutations or alterations in its expression are discovered to be associated with particular pathologies.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR signaling, which can impact protein synthesis and potentially influence KIAA0930 functions. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases, impacting chromatin structure and possibly influencing KIAA0930 expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, potentially impacting protein degradation processes relevant to KIAA0930. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibitors of the PI3K/Akt pathway might impact signaling pathways relevant to KIAA0930. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibitors of the MAPK/ERK pathway might influence signaling pathways relevant to the function of KIAA0930. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine inhibits autophagy, potentially affecting KIAA0930 if it's involved in autophagic processes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibiting NF-κB signaling might indirectly influence KIAA0930 activity if it's involved in related pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibitors of JAK/STAT signaling might indirectly influence KIAA0930 if it's involved in these pathways. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, potentially affecting the epigenetic regulation of KIAA0930. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blockers might impact cellular signaling and processes relevant to KIAA0930. | ||||||